Keywords: Japan, Merck Serono, Erbitux, GlaxoSmithKline, Flu vaccine, Merck KGaA
News from Japan: Merck Serono’ Erbitux gets extended use; GlaxoSmithKline seeks acquisitions and sees flu vaccine order reduced
Article | 29 March 2010
Merck Serono, a division of German drug major Merck KGaA says that Erbitux (cetuximab) can now be used in Japan ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
